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Abstract
Distal cholangiocarcinoma is a rare malignant condition arising from the epi-
thelial cells of the biliary tract. Surgical resection is the only curable alternative for 
patients with this disease. True resectability is often determined by surgical explo-
ration. Duodenopancreatectomy is an extremely high-demanding technique and is 
the only one that can be potentially curable for patients diagnosed with resectable 
distal cholangiocarcinoma. Long-term survival may be achieved only in selected 
patients, undergoing duodenopancreatectomy, especially in patients where R0 
margins are achieved. Perineural extension, pancreatic invasion, and lymph nodes 
involvement are the main risk factors for recurrence. Palliative biliodigestive diver-
sion or endoscopic internal drainage of the biliary tree is alternative for patients 
with unresectable tumors. Although the prognosis after surgical treatment of distal 
common bile duct malignancy is better than for other periampullary tumors, the 
continuous progresses made in the field of surgical therapy and oncological treat-
ment may lead to an improvement in the outcome of this neoplastic pathology.
Keywords: common bile duct tumors, surgical treatment, duodenopancreatectomy, 
jaundice palliation, laparoscopic pancreatic surgery
1. Introduction: general aspects
Biliary tract cancers are a group of neoplastic lesions originating from the 
epithelial cells of the biliary tract. This type of cancers are characterized by late 
diagnosis and also poor outcomes; they represent <1% of all cancers and approxi-
mately 3% of all gastrointestinal tumors [1] and affect elderly patients, especially 
men [2, 3]. Biliary tract cancers are categorized by their anatomical sites in distal, 
hilar, and intrahepatic cholangiocarcinoma. Intrahepatic cholangiocarcinoma is an 
entity defined by the fact that it is located proximally than the second-degree bile 
ducts. Perihilar cholangiocarcinoma represents the bile tract neoplasm character-
ized by the localization between the second-degree biliary ducts and the confluence 
between the cystic duct and the common bile duct. Distal cholangiocarcinoma is 
located from the confluence between the cystic duct and the common bile duct 
to the ampulla of Vater. Distal common bile duct cancer represents a periampul-
lary neoplasm, which is less common than pancreatic adenocarcinoma, being 
very difficult to distinguish between them [2]. Most of the biliary tract neoplasms 
are adenocarcinomas, which can be well, moderately, and poorly differentiated. 
Other types are considered to be rare [4]. Five-year survival rate is extremely poor, 
despite the fact that surgery and liver transplantation represent options for selected 
candidates suffering from perihilar cholangiocarcinoma. Many patients are still 
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not eligible for surgical treatment because of the advanced locoregional stage at the 
moment of diagnosis [1]. In order to obtain a higher survival rate, the multimodal 
treatment (surgery, chemotherapy, radiotherapy) should be considered in all stages 
of disease [5]. Regarding the chemotherapy, gemcitabine and cisplatin are usually 
used for treating inoperable cases. For intrahepatic cholangiocarcinoma, locore-
gional therapies were developed, but there is no conclusive evidence [2]. Perihilar 
localization is encountered in about 50% of the cases. The distal topography is 
found in approximately 40% of biliary tract cancers and the intrahepatic disease 
in less than 10% [6]. The epidemiology of these tumors is still poorly understood. 
Distal cholangiocarcinoma has a better prognosis and cure rate when compared to 
the pancreatic adenocarcinoma, but it still remains a high lethal medical condition. 
It is very important to make sure that a multidisciplinary approach is considered 
when dealing with distal cholangiocarcinoma [7].
2. Surgical treatment of distal cholangiocarcinoma: indications
2.1 Indications for radical treatment
Only a small number of patients are suitable for surgical treatment. In order to 
submit a patient for surgery, an assessment is mandatory, and it relies on accurate 
imaging and endoscopic techniques to assess the localization of the tumor and also 
the local and metastatic extent. In order to obtain an accurate staging and diagnosis, 
imaging should be done prior to biopsy. Ultrasound and CT are useful imaging tools 
for the staging of distal cholangiocarcinoma, but MRI with contrast angiography is 
the most accurate for assessing the biliary tract and the possible invasion of nearby 
vascular structures. The use of PET-CT scan is limited because of the presence 
of cholangitis, which can make the interpretation very difficult. The histological 
diagnosis is usually obtained by ERCP. The tissue sample can also be obtained by 
performing an endoscopic ultrasound with fine needle aspiration [8]. The selection 
of patients for surgery requires preoperative staging and surgical exploration (lapa-
roscopy) in order to exclude the patients with unresectable or metastatic disease. A 
biopsy is not mandatory in the cases when there is a high index of suspicion [9].
In order to obtain the best long-term outcome, tumor resection with clear 
margins is mandatory. The main objective is represented by an aggressive resection 
strategy [10]. Distal cholangiocarcinomas encounter the highest rate of resectability 
when compared to hilar or intrahepatic cholangiocarcinomas [11]. The overall 5-year 
survival rate following curative surgery is between 16 and 52% in cases of distal 
cholangiocarcinoma. The operation generally requires a duodenopancreatectomy 
with typical reconstruction. In few cases, when the disease is extensively involving 
the biliary tract, a pancreaticoduodenectomy associated with a hepatic resection 
might be required. However, if there is a case of distant nodal extent, combined pan-
creatic and hepatic resections are not recommended due to the high morbidity and 
mortality rates that this operation presents. The guidelines recommend that a biliary 
drainage should be considered prior to radical resection in patients with jaundice. 
However, the need of biliary drainage should be assessed by a multidisciplinary team 
with high experience in dealing with distal cholangiocarcinomas [12].
2.2 Prognostic factors: operability criteria
There are two main predictors of survival after surgery: the status of surgical 
margins and lymph node involvement. Lymphadenectomy should be performed in 
the area of the pancreatic head and it is considered to be a vital part of the surgical 
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intervention. Performing a frozen section examination of the proximal biliary tract 
margin should be considered in order to be sure that oncological surgical criteria are 
fulfilled [13, 14].
Resectability criteria:
• The absence of retropancreatic and paraceliac lymph nodal involvement
• The absence of liver metastases
• The absence of invasion of the main hepatic artery
• The absence of disseminated disease
3. Indications for palliative treatment: unresectable tumors
Locally advanced, unresectable, distal cholangiocarcinomas are divided into 
three main categories as it follows:
1. Microscopic positive margins (R1) after resection
2. Locally advanced, unresectable, from the moment of presentation
3. Recurrence after intent of curative treatment
The prognosis of unresectable cholangiocarcinomas is extremely poor: 
6–12 months. The goal for these patients is to relieve symptoms and obtain a better 
quality of life. Also, it is well known that tumor debulking does not have a role and 
should be avoided in advanced cases of cholangiocarcinoma. Recently, chemotherapy 
combined with local therapies and biological therapies proved to be associated with 
a significant improvement in the survival rate. However, because of the rarity of the 
disease, many of these treatment options are assessed only in small studies and require 
to be validated by large prospective randomized trials [8]. Surgical treatment is con-
traindicated in cases of metastatic disease of the liver, lung, and peritoneum or in cases 
that present lymph nodes involvement beyond the head of the pancreas. Patients with 
unresectable or metastatic disease are considered for the palliation of jaundice. This is 
made either by a surgical bypass or, most frequently, by ERCP with the placement of 
a biliary stent. In cases of unresectable disease, a biopsy is mandatory in order to con-
tinue with any type of further treatment. Treatment options include the enrollment 
into a clinical trial, chemotherapy, radiotherapy, or chemoradiation procedures. There 
are trials that suggest the benefit of chemotherapy over best supportive care alone with 
reported overall survival rate of 9.5 versus 4.5 months [15, 16]. Another possibility 
for these patients is represented by chemoradiation. This way of treatment provides 
control of the symptoms and prolongs the overall survival rate. The most studied 
chemotherapeutic agent used in combination with radiotherapy was fluorouracil [17].
For patients with microscopically positive margins after surgery, the most 
recommended way of treatment consists of postoperative systemic chemotherapy 
combined with adjuvant chemoradiotherapy in conventional doses of radiation.
In cases of locally advanced and recurrent disease, the use of conventional doses 
of radiations has the role of relieving pain and may have a role in the decompression 
of the biliary tract [18].
Photodynamic therapy consists of intravenous injecting of a porphyrin photosen-
sitizer combined with the endoscopic application of light on the tumor site.  
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This innovative technique leads to the death of the tumoral cell by generating free 
radicals of oxygen. Some studies suggest that photodynamic therapy combined with 
biliary decompression obtained after stenting provides a benefit in the overall sur-
vival rate of these patients [19–21]. Nowadays, photodynamic therapy is studied as a 
neoadjuvant condition. It is presumed that the rate of postoperative negative margins 
can be increased by submitting patients to neoadjuvant photodynamic therapy [22].
One of the most important aspects when dealing with locally advanced, unre-
sectable, distal cholangiocarcinomas is represented by the palliation of jaundice. 
This can be realized by performing a surgical by-pass or by endoscopic placement 
of a stent. In patients who are found to suffer from an unresectable cholangiocar-
cinoma during a laparotomy, a surgical bypass is preferred. On the other way, in 
cases that the unresectable condition is diagnosed by imagining or laparoscopy, the 
endoscopic placement of a biliary stent is preferred. In most cases, the palliation 
of jaundice is obtained by an endoscopic approach [23, 24]. The most common 
relapse pattern is represented by local recurrence. Positive margins and lymph node 
involvement are predictive risk factors for local recurrence. The typically sites of 
metastases are the liver and the peritoneum.
4. Surgical technique and approach
4.1 Duodenopancreatectomy
Duodenopancreatectomy represents a very complex surgical intervention. It is 
performed in cases of resectable periampulary tumors: distal cholangiocarcinoma, 
tumors of the pancreatic head, tumors of the ampulla of Vater, and tumors of the 
duodenum [25].
The surgical intervention begins with either a median or bilateral subcostal inci-
sion (in thin patients, a median incision is preferred). First important step during 
a duodenopancreatectomy is to search for distant metastases. Once the surgeon 
rules out the presence of liver or peritoneal metastases, the Kocher maneuver is 
performed in order to identify the relation of the tumor with the retroperitoneal 
structures and especially the superior mesenteric artery. The superior mesenteric 
artery is dissected beginning from the right side of the Treitz’s ligament, in order 
to exclude the tumoral involvement of the artery. This procedure is known as 
artery-first approach. Access to the omental bursa is gained by the division of the 
gastrocolic ligament. In order to mobilize the hepatic flexure of the colon, care-
ful dissection of the avascular plane located between the hepatic flexure and the 
duodenum must be performed. Once the colonic flexure is mobilized caudally, the 
Kocher maneuver can be extended in order to allow the access to the D3 portion of 
the duodenum (Figure 1). Now, the gastroepiploic vein is divided and the superior 
mesenteric vein appears on the inferior margin of the pancreas. In order to complete 
this step of the surgical intervention, a tunnel is made between the neck of the 
pancreas and the portal vein (Figure 2). Further, the dissection continues in the 
supraduodenal region as it follows. Cholecystectomy is performed in the classical 
way. After the dissection of the Callot triangle, the common bile duct is divided just 
proximal from the origin of the cystic duct. After the cystic artery is identified, it is 
closed by ligation and divided. A very important step for obtaining best oncological 
outcome is represented by the lymphadenectomy of the hepatoduodenal ligament 
continued toward the celiac trunk. During this dissection, the proper hepatic artery, 
originating from the common hepatic artery and the main branches of the celiac 
trunk, can be isolated. The gastroduodenal artery is now divided near its origin 
(Figure 3). In order to obtain the preservation of the pylorus (optional step), the right 
5
Surgical Treatment of Distal Common Bile Duct Malignancy
DOI: http://dx.doi.org/10.5772/intechopen.85366
gastric and right gastroepiploic arteries should be divided. After the mobilization 
of the first 2 cm of the duodenum is performed, the portal vein is widely exposed. 
The superior and inferior pancreatic vessels are now ligated by placing two sutures 
on both the superior and inferior borders of the pancreas. Those two sutures are 
extremely important for minimizing the bleeding after transection of the pancreas. 
A tunnel is now fully created between the portomesenteric trunk and the posterior 
surface of the pancreatic neck. The Treitz angle and the first jejunal loop are now 
Figure 1. 
Kocher maneuver; laparoscopic approach (from the personal archive of the authors). P = pancreatic head; 
D = duodenum; SMV = superior mesenteric vein.
Figure 2. 
Dissection of the SMV and PV from the pancreatic isthmus; laparoscopic approach (from the personal archive 
of the authors). P = pancreatic head; SMV = superior mesenteric vein; PV = portal vein.
Figure 3. 
Dissection of the gastroduodenal artery; laparoscopic approach (from the personal archive of the authors). 
L = liver; HA = hepatic artery; GDA = gastroduodenal artery.
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dissected and divided so that the jejunum can be tractioned into the supramesocolic 
compartment. The dissection along the superior mesenteric artery and vein is carefully 
performed using a bipolar electrocautery and clips or ligatures. The venous (portal, 
superior mesenteric, venous confluent) resection, if required, is performed in the last 
step (Figure 4A and B). By gently retracting the portal vein, in order to expose the 
retroportal tissue, the venous branches that drain directly into the portal vein are iden-
tified, ligated, and divided. The transection of the pancreatic neck is now performed 
by using a scalpel (classic or harmonic). It is very important to obtain a perfect hemo-
stasis at the level of the pancreatic stump. This is obtained by placing nonabsorbable 
monofilament sutures. Some authors consider that by using the bipolar or monopolar 
cautery, an insecure hemostasis is obtained and also the pancreatic tissue can be dam-
aged, the fact that may compromise future anastomosis. As a final step of the extirpa-
tive phase, the duodenum (in pylorus preserving technique) is divided using a linear 
stapler. Now the specimen is removed and sent for histopathological examination. The 
pancreatic stump is now mobilized in order to obtain a tension-free pancreatic anasto-
mosis (with the stomach or the jejunum). The second main phase of this very complex 
operation is the reconstructive phase. Now, in order to obtain the continuity of the 
digestive tract, three anastomoses must be performed. Firstly, the pancreatic stump is 
anastomosed either with the stomach (posterior surface) or the jejunum. As long as 
the basic principle of a safe anastomosis is considered, any technique may be success-
ful. The bilioenteric anastomosis is performed usually as an end to side single layer 
anastomosis (Figure 5). Another important aspect is that the bilioenteric anastomosis 
is performed on the antimesenteric margin of the jejunum. The final reconstruction is 
represented by the gastrojejunostomy (or duodenojejunostomy if pylorus preserving 
technique was used). Most authors prefer an antecolic gastrojejunostomy performed at 
approximately 50 cm downstream from the biliodigestive anastomosis.
Finally, abdominal drains and nasogastric tube are placed. A feeding jejunos-
tomy may now be performed. After a final evaluation of hemostasis, the musculo-
aponeurotic plane is closed and the skin is sutured.
4.2 Palliative surgery
There are different surgical approaches in order to obtain jaundice palliation. 
However, these procedures are rarely performed due to the fact that they were 
largely replaced by endoscopic placing of stents [26].
Figure 4. 
Vascular resection of a tumor with invasion in the portal vein; open approach (from the personal archive of 
the authors). L = liver; PV = portal vein; SMV = superior mesenteric vein; TU = tumor. (A) Before vascular 
resection; and (B) after vascular reconstruction.
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In order to perform a bilioenteric bypass, the cholecystectomy is a mandatory step. 
The most important moment in performing the cholecystectomy is the dissection of 
Callot triangle, where the elements of the gallbladder pedicle are located. The isola-
tion, ligation, and resection of the cystic duct and artery are performed at this level. 
The next step of the procedure is the dissection of the gallbladder from its hepatic 
fossa using the electrocautery or scissors.
4.2.1 Choledochoduodenostomy
Choledochoduodenostomy is a useful operative technique when dealing with 
unresectable distal cholangiocarcinoma. After performing a cholecystectomy, a 
supraduodenal longitudinal choledochotomy is performed and the biliary tract is 
explored. By performing a wide Kocher maneuver, the duodenum can be mobi-
lized in order to obtain a tension-free anastomosis. A longitudinal duodenotomy 
is performed on the D1 portion of the duodenum. Two corner sutures are placed 
between the ends of the duodenotomy and the middle parts of the choledochotomy. 
Another corner suture is placed between the inferior pole of the choledochotomy 
and the midposterior point of the duodenotomy. Now the posterior raw of sutures is 
applied and tied. Next, the forth corner suture is applied between the superior pole 
of the choledochotomy and the midanterior point of the duodenotomy. This makes 
it easier to perform the anterior layer of sutures. Like other biliodigestive anastomo-
sis, single-layer sutures are recommended (Figure 6) [26].
Figure 5. 
Biliojejunal anastomosis; laparoscopic approach (from the personal archive of the authors). CBD = common bile duct.
Figure 6. 
Side-to-side choledochoduodenostomy for unresectable neoplasia; laparoscopic approach (from the personal 
archive of the authors). CBD = common bile duct.
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4.2.2 Choledochojejunostomy and hepaticojejunostomy
A hepaticojejunostomy can be performed either on the left or the right hepatic 
ducts. This surgical intervention is performed through a right subcostal incision. 
Extending the incision toward the xiphoid process or with a left subcostal incision 
provides a good approach in order to perform the biliary-enteric bypass. By remov-
ing the gallbladder, a better access to the extrahepatic biliary ducts is gained.
In order to approach the left hepatic duct, the teres ligament is divided to obtain 
a better exposure of the left hemiliver. On the visceral surface of the left hemiliver, 
the left hepatic duct goes together with the left branch of the portal vein and they 
are found together into a peritoneal reflection. The best way to gain access in this 
area is by lowering the hilar plate.
On the other hand, the right hepatic duct can be approached by dissecting along 
the base of IVb segment of the liver. In this way, the biliary confluent is well visual-
ized. As it often happens, the right hepatic duct is too short in length and small 
hepatic parenchyma incisions may be needed in order to visualize the intrahepatic 
right portal pedicle.
Once the access is gained, a 60–70 cm Roux en Y jejunal loop is prepared and 
delivered through a breach in the mesocolon located on the right from the middle colic 
pedicle. The posterior row of sutures is now performed in order to secure the duct 
mucosa to the jejunal mucosa. With the anterior sutures retracted upward, the poste-
rior row is now tied up. Further, the anterior row is completed by suturing the jejunal 
mucosa. Finally, the anterior layer is tied and the anastomosis is complete [26].
In order to perform a choledochojejunostomy, the technique is the same, except 
the location on the common bile duct where the anastomosis is done.
4.2.3 Endoscopic and percutaneous drainage
If the malignant disease is too advanced and a surgical curative treatment is not 
suitable, biliary drainage needs to be established in order to lower the effects of 
hyperbilirubinemia. Percutaneous transhepatic drainage and endoscopic retrograde 
cholangiopancreatography are widely used for the palliation of jaundice.
Percutaneous transhepatic biliary drainage is a procedure performed under fluo-
roscopic or ultrasound guidance. With increased expertise and better instrumenta-
tion, the technical success rate is of ~90–95% with fewer complications rates [27].
ERCP is accepted as the preferred procedure worldwide as it is a comparably 
safer procedure with relatively fewer contraindications. Absolute contraindica-
tions for ERCP are as follows: pharyngeal or esophageal obstruction and active 
coagulopathy [28, 29]. This procedure also has some relative contraindications, such 
as the presence of acute pancreatitis or severe cardiopulmonary disorder. Unlike 
percutaneous transhepatic drainage, burden of percutaneous drainage catheter and 
bag is obviated, which further compounds the psychological burden of terminally 
ill patients. In the current scenario, in cases of distal common bile duct obstruction, 
ERCP is the preferred technique unless contraindicated, for which the percutaneous 
approach is performed [27].
5. Results
Despite the fact that biliary tract cancer is associated with a high mortality rate, 
patients diagnosed with distal cholangiocarcinoma have a better survival rate when 
compared with other periampullary cancers. The poor prognosis is due to the fact 
that many patients are suffering from an advanced stage at the time of surgery; this 
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is proved by the high incidence of lymph node involvement, perineural extension, 
and lymphatic and vascular invasion [30]. Significant improvement of short-term 
outcome has been encountered lately due to the development of surgical techniques 
and perioperative management. Nowadays, it is considered that the mortality rate 
following surgery is less than 5%, when talking about high-volume centers [30, 31]. 
The 5-year overall survival rate is now considered to range from 13 to 54%. The 
poor prognosis is due to the fact that biliary tract cancer encounters two main forms 
of extension: submucosal spreading and superficial spreading. Those two cause 
the high rate of positive margins obtained in surgery. This is why an intraoperative 
frozen examination of the margins is extremely important [30]. If R0 resection 
is performed, the overall survival rate at 5 years is considerably increased from 
0–40% (R1 margins) to 27–60% (R0 margins) [30, 32]. Surgeons worldwide make 
efforts to improve the prognosis of this disease. Some of them claim that extended 
lymphadenectomy combined with the dissection of nerve plexus surrounding 
major blood vessels improves the outcome [30]. However, there are still a lot of 
controversies around this strategy. A very controversial aspect is represented by 
postoperative adjuvant chemotherapy. There are studies that show no significant 
difference in the 5-year overall survival rate between those who receive adjuvant 
chemotherapy (gemcitabine, paclitaxel, oxaliplatin, fluorouracil) when compared 
to those who have not [33]. In order to establish significant prognostic factors for 
distal cholangiocarcinoma, several studies were conducted. They assessed prognos-
tic factors such as perineural extent, lymph node involvement, and the histological 
differentiation of the tumor. Studies that analyze the prognostic factors for 5-year 
overall survival rate of patients diagnosed with distal cholangiocarcinoma and 
submitted to surgery with curative intent conclude that the presence of R1 margins, 
lymph node involvement, perineural invasion, lymphatic and vascular extension, 
pancreatic invasion, and the presence of tumors >T3 is associated with poor prog-
nosis. Those studies conclude that obtaining R0 margins substantially improves the 
outcome and is one of the most important prognostic factors [30]. In order to obtain 
better outcome, more accurate diagnostic modalities should be developed.
6. Future perspectives
Laparoscopic duodenopancreatectomy represents one of the most advanced 
abdominal interventions and it still has small widespread so far (Figures 1–3, 5, 7). 
The complexity of this procedure is due to the facts that dissection of the portal 
vein, lymphadenectomy, and dissection of the uncinate process are extremely high 
demanding. When comparing to other minimally invasive procedure, the rate of 
conversion is higher. This is due to the adhesions to large vascular structures and 
uncontrollable bleeding. Reported rates of conversion are ranging between 0 and 
40%. The difference between the reported rates of conversion arises from the 
liberalization of intraoperative decision to convert [34]. The mean operating time 
is significantly longer during minimally invasive duodenopancreatectomies when 
compared to the open procedure. In addition to the complexity of the resection  
step, performing the reconstructive step is technically high demanding and of 
course, time-consuming. It is considered that the learning curve extends for sev-
eral years, in order to obtain good outcome [35, 36]. Hybrid approach might be a 
solution in order to accumulate experience. In this type of surgical approach, the 
anastomoses are performed through a small laparotomy [33, 34]. Hybrid approach 
is considered to provide a safely development to a totally laparoscopic method [37]. 
The learning curve can be shortened by practicing simple sutures and then gastro-
intestinal anastomoses on the simulator or animal models. There are studies that 
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demonstrate favorite outcomes in case of using a robotic and laparoscopic hybrid 
approach. In this case, the resection is performed laparoscopically and then, 
with robotic assistance, the surgeon performs the reconstructive step [38]. Data 
showed a lower blood loss in the minimally invasive approach when compared to 
the open technique. As a consequence, there is a lower need of transfusion, which 
is an objective outcome. However, there is a high risk of perioperative morbidity 
and mortality, the fact that limits the development of minimally invasive duode-
nopancreatomy. Literature concludes that the open approach has a morbidity rate 
between 23 and 66% with a mortality of 3–5% in high-volume centers [39, 40]. 
The minimally invasive technique has a morbidity ranged between 18.2 and 87.5% 
with a mortality rate of 0–6.9%, comparable to the open approach. The main 
complication following duodenopancreatectomies is considered to be pancreatic 
fistula. There are comparable rates of complications (severe pancreatic fistula, 
delayed gastric emptying, pancreatic stump hemorrhage) when comparing the 
open technique with minimally invasive [41], the fact that encourages to consider 
the use of the minimally invasive approach as safe as the open technique. However, 
it is necessary that large prospective studies to be done, in order to obtain a 
comparison between these two techniques regarding long-term outcomes such as 
survival rate and quality of life [42].
The use of robotics may turn useful in promoting the application of a minimally 
invasive approach in major procedures in the treatment of distal cholangiocarci-
noma. Robotic surgery has proven to be feasible, but its oncologic adequacy is yet to 
be demonstrated by larger studies.
7. Key points
• Jaundice is the most important clinical manifestation of this neoplastic disease.
• Surgical resection is the only curable alternative for patients with distal 
cholangiocarcinoma.
• The treatment of choice for resectable tumors is duodenopancreatectomy.
Figure 7. 
Port placement for laparoscopic duodenopancreatectomy (from the personal archive of the authors).
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• Duodenopancreatectomy can be performed either open or laparoscopically, in 
high-volume centers.
• The palliation of jaundice is the cornerstone for treatment of the advanced distal 
cholangiocarcinoma.
• Long-term survival may be achieved only in selected patients, undergoing duode-
nopancreatomy, especially in patients where R0 margins are achieved.
• Perineural extension, pancreatic invasion, and lymph nodes involvement are 
the main risk factors for recurrence.
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